Vaxcyte (PCVX) Stock

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a law firm focused on shareholder lawsuits, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) failed to fulfill their responsibilities to shareholders. The inquiry is related to possible self-dealing actions. Shareholders might be eligible for compensation and changes in corporate governance.

Carillon Tower Advisers, an investment management firm, published its third quarter 2024 investor letter for the "Carillon Eagle Small Cap Growth Fund." You can download the letter here. After facing losses in the second quarter, small-cap stocks saw a significant rise in the third quarter, with the Russell 2000 Growth Index increasing by 8.41%, although it still lagged behind the Russell 2000 Value Index.

The FDA has approved the Investigational New Drug Application for VAX-31 for infants, and the company aims to start the Phase 2 study by the end of January 2025. For adults, the FDA has given Breakthrough Therapy Designation to VAX-31, and the company intends to begin the Phase 3 pivotal study by mid-2025.

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on developing advanced vaccines to combat bacterial diseases, has announced that its management will take part in a fireside chat at the 2024 Cantor Global Healthcare Conference. This event is scheduled for Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.

Vaxcyte's XpressCF platform allows for the creation of vaccines that can target a wide range of diseases, addressing the challenges of older cell-based methods. The company's main products, VAX-31 and VAX-24, focus on invasive pneumococcal disease (IPD) and offer better protection than other options available. The early results for VAX-31 showed it is safe and effective, setting it up for further testing in Phase 3 trials by mid-2025.

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on developing advanced vaccines to combat bacterial diseases, has completed its public offering of 12,087,378 shares of common stock at a price of $103.00 each, along with pre-funded warrants for 2,427,184 shares at $102.999 each. This offering also included the full exercise of an option by underwriters to buy an additional 1,893,203 shares at the same public price. Vaxcyte raised around $1.5 billion from this offering before deducting any fees or expenses.

Vaxcyte's stock rose sharply this week after positive Phase 1/2 results for its VAX-31 vaccine, which demonstrated better immune responses than Pfizer's Prevnar 20. The VAX-31 vaccine targets 31 strains and aims to address more than 95% of invasive pneumococcal disease in U.S. adults, with Phase 3 trial results anticipated by mid-2026. Although there is competition from Merck and GSK, Vaxcyte's unique XpressCF platform gives it a strong advantage in the expanding pneumococcal conjugate vaccine market.

Vaxcyte Inc.'s shares dropped by 3% on Friday morning after the company finished a stock offering that is projected to raise $1.42 billion.

Vaxcyte, a company that develops vaccines and is currently in the clinical stage, announced on Wednesday that it plans to raise $1.3 billion by selling common stock and warrants. This news comes after their shares reached a record high due to positive results from a vaccine trial.